The US Food and Drug Administration (FDA) recently granted Usona Institute, Madison, Wisconsin, the Breakthrough Therapy designation for psilocybin in the treatment of patients with major depressive disorder (MDD).
At both lower and higher doses, a yoga and breathing intervention improved symptoms of depression and anxiety in a group of people with major depressive disorder (MDD), according to a study published recently in the Journal of Psychiatric Practice.
People with mood or anxiety disorders demonstrate shared abnormalities in brain regions involved in emotional and cognitive control, according to a meta-analysis of brain scans published online in JAMA Psychiatry.
Antidepressant use appears to be safe, according to a systematic umbrella review of 45 meta-analyses spanning more than 1000 observational studies. Researchers published findings from their review online in JAMA Psychiatry.
SAN DIEGO—Mental health clinicians aren't talking to their patients enough about sexual dysfunction commonly associated with depression and its treatment, Anita Clayton. MD, stated at Psych Congress 2019.
SAN DIEGO—Added to standard-of-care treatment, esketamine nasal spray rapidly reduced depressive symptoms in patients at imminent risk of suicide, according to two phase 3 trials presented at Psych Congress 2019.
Exercise is effective for both preventing and treating depression, yet the intervention does not receive the acknowledgement it warrants in clinical practice, reports a new review and meta-analysis published in Current Sports Medicine Reports.